Seattle Genetics Announces Pivotal ADCETRIS™ (Brentuximab Vedotin) Hodgkin ... MarketWatch (press release) ADCETRIS is being evaluated in a phase III clinical trial (the AETHERA trial) for patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant (ASCT), a phase II trial for relapsed or refractory CD30-positive non-Hodgkin ... |
